Results 41 to 50 of about 30,839 (241)

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]

, 2016
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet, Bhatia, Ravi, Campbell, Victoria L., Chu, Su, Gaal, Karl, Holyoake, Tessa L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Zhang, Bin   +9 more
core   +1 more source

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Anderson, Ashley Hamilton, Bhatia, Bin Zhang, Branford, Carsten Müller-Tidow, Chen, Chomel, Chu, Copland, Corbin, Daley, Druker, Druker, Druker, Elaine K. Allan, Felsher, Franck E. Nicolini, G. Vignir Helgason, Gabert, Gorre, Gothert, Graham, Hamilton, Hayette, Holyoake, Hughes, Hurtz, Jiang, Jordan, Jordanides, Jorgensen, Konig, Konig, Konig, Koschmieder, Li, Lombardo, Lugo, Mirle Schemionek, Myssina, Notta, Pellicano, Ravi Bhatia, Samanta, Samanta, Schemionek, Scott, Shachaf, Shah, Sharma, Sharma, Sobrinho-Simoes, Steffen Koschmieder, Svetlana Myssina, Talpaz, Tessa L. Holyoake, Valerie G. Brunton, Wang, Weinstein, Weisberg, White   +61 more
core   +1 more source

Prevalence of BCR-ABL T315I Mutation in Different Chronic Myeloid Leukemia patients Categories.

Pakistan Journal of Biological Sciences, 2022
Background and Objective: Chronic Myelogenous Leukaemia (CML) is a clonal myeloproliferative tumor distinguished by the existence of the Philadelphia chromosome (Ph) resulting from the t (9, 22) (q34, q11) translocation.
Hala Elsir Khair, Babker Ahmed Mohamed, Bakri Yousef Nour, Hisham Ali Waggiallah   +3 more
semanticscholar   +1 more source

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S, Burger H, Burgess MR, Cortes J, Crossman LC, Donato NJ, Druker BJ, Gambacorti-Passerini C, Giles F, Hochhaus A, Hughes TP, Iacobucci I, Kantarjian H, Lahaye T, Mahon FX, Melo JV, O'Hare T, Quintas-Cardama A, Rousselot P, Sleijfer S, Soverini S, Weisberg E   +21 more
core   +1 more source

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? [PDF]

Reviews in Clinical Medicine, 2015
Chronic myelogenous leukemia is a myeloproliferative disorder presenting with anemia, elevated blood granulocytosis and the presence of immature granulocytes, basophilia, frequently thrombocytosis and spleen enlargement.
Hossein Rahimi, Zahra Mazloum Khorasani, Saeedeh Shariati   +2 more
doaj   +3 more sources

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
A Foudi, A Gothot, A Strife, A Wilson, AHG Hamilton, AR Oller, Bayard Clarkson, BJ Druker, C Cobaleda, C Roche-Lestienne, CH Jamieson, Christophe Fraser, CL Sawyers, D Dingli, E Passegue, F Arai, F Michor, F Michor, F Michor, Franziska Michor, GB Bradford, H Glimm, HG Jorgensen, I Roeder, J Cashman, J Cortes, Jasmine Foo, JC Wang, JD Rowley, JF Apperley, KJ Hope, KW Orford, L Ponchio, M Holtz, Mark W. Drummond, ME Gorre, MJ Mauro, MW Drummond, N Uchida, NL Komarova, NL Komarova, NP Shah, P Rousselot, PS Kim, S Branford, S Branford, S Merante, SM Graham, T Higashi, T Holyoake, T Lapidot, T Reya, Tessa Holyoake, TL Holyoake, W Ghanima, WR Bruce, Y Wang   +56 more
core   +4 more sources

Chronic myelogenous leukemia presenting with Morel Lavallée lesion: A case report of a rare presentation

Clinical Case Reports, 2022
Chronic myelogenous leukemia is a myeloproliferative neoplasm characterized by the BCR‐ABL1 fusion gene and the development of the Philadelphia chromosome, which leads to an increase in granulocytes and bone marrow myeloid precursors in the blood, it can
Sara S. I. Mohamed, Hana Mahmoud Qasim, Ahmed Mahfouz, Maab A. Osman, Ashraf O. E. Ahmed, Safa H. Al‐Azewi, Mohamad A. Yassin, Shehab Fareed   +7 more
doaj   +1 more source

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks [PDF]

, 2011
The resistance of leukemic stem cells in response to targeted therapies such as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of multiple signaling pathways and molecules, including TGFβ, AKT, and FOXO transcription factors ...
Austin, Bernardi, Bhatia, Brunet, Carayol, Chen, Chen, Druker, Duy, Fernández de Mattos, Francesca Pellicano, Graham, Hurtz, Ilaria, Ito, Komatsu, Lee, Mahon, Naka, Neubauer, Neviani, Neviani, Peng, Rowley, Samanta, Stambolic, Tessa L. Holyoake, Tothova, Xie, Yilmaz, Zhou   +30 more
core   +2 more sources

Mutational analysis of T315I in patients with chronic myeloid leukemia who did not respond to second-generation tyrosine kinase inhibitors

Iraqi Journal of Hematology, 2020
BACKGROUND: Chronic myelogenous leukemia (CML) is a hematological stem cell disorder that associates with mutations in BCR-ABL. Although mutations identified in more than 30 different amino acids, the highest degree of resistance was associated with ...
Riyam Qusay Ibrahim Al-Jadir, Jaffar Nouri Alalsaidissa   +1 more
doaj   +1 more source

Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy [PDF]

Vojnosanitetski Pregled, 2012
Background/Aim. Introducing tyrosine kinase inhibitors (TKIs) has essentially changed curative approach, to be precise, clearly improved treatment efficacy for chronic myeloid leukemia (CML).
Stamatović Dragana, Balint Bela, Tukić Ljiljana, Elez Marija, Tarabar Olivera, Todorović Milena, Todorić-Živanović Biljana, Ostojić Gordana, Tatomirović Željka, Marjanović Slobodan, Malešević Milomir   +10 more
doaj   +1 more source